Citations

Clear

2 citation(s) found for "Smith, Melissa".

An Overview of Cannabinoid Interactions With Common Pediatric Antineoplastic Agents
Zaman, Shatila, Schatz, Mollie, Kuhn, Alexis , O’Keefe, Madeleine, Greenmyer, Jacob R. , Smith, Melissa K, Martin, Catherine E. , Kuhn, Alexis K , O'Keefe, Madeleine B, DeFino, Catherine E.

Mayo Clinic

Pediatric Blood & Cancer | April 30, 2026 | Volume: 73 | Issue: 7 | Pages: No page available

10.1002/1545-5017.70336 | PMID 42057496 Get It

ABSTRACT As interest in the use of cannabinoids for supportive care in pediatric cancers grows, there are emerging concerns about potential interactions with antineoplastic agents. This review provides an overview of potential drug–drug interactions between cannabinoids and 25 antineoplastic agents commonly used in pediatric hematology/oncology. Antineoplastic agents were stratified into low, medium, or high interaction risk based on the potential impact of cannabinoids on metabolic and/or pharmacodynamic pathways. The antineoplastic agents identified as high risk for interactions with cannabinoids included cyclophosphamide, doxorubicin, etoposide, ifosfamide, irinotecan, vinblastine, and vincristine. Key mechanisms of interaction include inhibition of cytochrome P450 enzymes and UDP‐glucuronosyltransferases and modulation of drug transporters such as P‐glycoprotein and breast cancer resistance protein. There is emerging evidence of a synergistic effect between cannabinoids and antineoplastic agents such as temozolomide, vinblastine, vinorelbine, and irinotecan. Pediatric patients exhibit developmental differences in drug metabolism and transporter expression, yet most pharmacokinetic data on cannabinoids are extrapolated from adult studies. There is a lack of pediatric‐specific safety, efficacy, and dosing data that underscores the need for age‐appropriate studies to ensure safe and effective integration of cannabinoids in pediatric cancer care.
Consultation patterns before and after embedding pediatric palliative care into a pediatric hematology/oncology clinic
Greenmyer, Jacob R. , Ngo, Tiffany , Smith, Melissa M. , Collura, Christopher A. , Schiltz, Brenda , McCarthy, Sarah R. , McCarthy, Sarah , Smith, Melissa, Collura, Christopher, McCarthy, Sarah R , McCarthy, Sarah R.

Mayo Clinic

Pediatric Blood & Cancer | September 15, 2023 | Volume: 70 | Issue: 12 | Pages: No page available

10.1002/pbc.30663 | PMID 37710331 Get It

AbstractIntroductionPalliative care is a critical component of pediatric oncology care. Embedded pediatric palliative care (PPC) is relatively new in pediatric hematology/oncology (PHO) and may improve access, utilization, and quality of PPC. In June 2020, the Mayo Clinic PPC service transitioned from an afternoon, physically independent clinic to an all‐day clinic embedded within PHO.MethodsRetrospective chart review was used to quantify consultation rates from PHO to PPC in 12‐month study periods before and after establishment of an embedded clinic. Changes in descriptive statistics and consult patterns were calculated. Study periods were compared using either chi‐square or Fisher's exact tests for categorical variables and Wilcox rank sum tests for continuous variables.ResultsThere was an 89% increase in consultations from PHO to PPC after initiation of an embedded clinic (n = 20 vs. n = 38 per 12 months). The absolute number of completed outpatient consults increased from three (15% of visits) pre‐embedment to fourteen (37%) post‐embedment (p = .082). The median number of days from first oncology visit to PPC assessment was unchanged after embedment (36 vs. 47 days, p = .98). Consults for solid tumors increased from 22% (n = 4) pre‐embedment to 60% (n = 18) post‐embedment (p < .05). Consults for symptom management increased from 60% (n = 12) to 87% (n = 33) (p < .05).ConclusionsEmbedment of PPC into a PHO workspace was associated with an increased number of total consults, outpatient consults, solid tumor consults, and consults for symptom management. Our “partial‐PPO” model allowed for provision of PPC in the outpatient oncology setting in a clinic where there is not enough volume to support a full‐time oncology‐focused clinician team.